H.C. Wainwright initiated coverage of Senti Bio (SNTI) with a Buy rating and $12 price target The firm believes the company’s allogeneic CAR-NK cell therapy platform has the potential to treat several cancer types including hematologic malignancies and solid tumors. It views Senti as an “underappreciated CAR-NK player with a differentiated platform with a near-term catalyst” in Q4.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks